What Barinthus Biotherapeutics plc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 11 | 11 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 11 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Oxford Sciences Innovation plc | Insider | Sep 09 | Tender Offer · U | −8,797,770 | $0.11 | −$977K | 0 |
| Dawes Karen A | Director | Sep 09 | Disposition to Issuer · D | −1,700 | — | — | 0 |
| Wright Robin | Director | Sep 09 | Disposition to Issuer · D | −48,256 | — | — | 0 |
| Phillips Anne M. | Director | Sep 09 | Disposition to Issuer · D | −3,000 | — | — | 0 |
| Morgon Pierre A. | Director | Sep 09 | Disposition to Issuer · D | −10,506 | — | — | 0 |
| Hooftman Leon | Chief Medical Officer | Sep 09 | Disposition to Issuer · D | −361,530 | — | — | 0 |
| Hooftman Leon | Chief Medical Officer | Sep 09 | Grant / award · A | +361,530 | — | — | 361,530 |
| Enright William | Chief Executive Officer | Sep 09 | Disposition to Issuer · D | −514,923 | — | — | 0 |
| Enright William | Chief Executive Officer | Sep 09 | Disposition to Issuer · D | −728,454 | — | — | 0 |
| Scheeren Joseph | Director | Sep 09 | Disposition to Issuer · D | −23,000 | — | — | 0 |
| Hammacher Alex | Director | Sep 09 | Disposition to Issuer · D | −3,000 | — | — | 0 |
| Scheeren Joseph | Director | Jun 26 | Open-market buy · P | +10,000 | $2.44 | +$24.4K | 23,000 |
| Wright Robin | Director | May 25 | Open-market buy · P | +13,750 | $2.66 | +$36.6K | 48,256 |
| Enright William | Chief Executive Officer | Mar 27 | Open-market sale · S | −15,000 | $2.42 | −$36.3K | 728,454 |
| M&G Alternatives Investment Management Ltd | 10% owner | Sep 30 | Other Transaction · J | −4,108,752 | — | — | 0 |
| M&G Investment Management Ltd | 10% owner | Sep 30 | Other Transaction · J | +4,108,752 | — | — | 5,197,349 |
| Ellis Christopher | Chief Operating Officer | Aug 25 | Open-market sale · S | −25,000 | $7.07 | −$177K | 75 |
| Ellis Christopher | Chief Operating Officer | Aug 25 | Open-market sale · S | −14,176 | $5.69 | −$80.7K | 25,075 |
| Ellis Christopher | Chief Operating Officer | Aug 25 | Exercise / conversion · M | +39,176 | $0.00 | +$15.7 | 39,251 |
| Griffiths Graham | Chief Business Officer | Aug 25 | Open-market sale · S | −10,000 | $7.39 | −$73.9K | 104,209 |
Loading...
